Suven Life Sciences announces promising results at 76th American Academy of Neurology Meeting
Suven Life Sciences, a clinical-stage biopharmaceutical company focused on the development of novel treatments for Central Nervous System (CNS) disorders, is set to present significant ... Read More
Suven Life Sciences announces positive results from Samelisant Phase-2 study
Suven Life Sciences, a pioneering biopharmaceutical company specializing in Central Nervous System (CNS) disorders, recently announced the successful completion of its Phase-2 proof-of-concept study for ... Read More
Suven Life Sciences set to begin samelisant phase 2 trial in narcolepsy
Suven Life Sciences has announced the successful completion of enrollment for its phase-2 proof-of-concept (PoC) clinical study to evaluate the safety and efficacy of samelisant ... Read More